New NCCN Guidelines for Pediatric Cancers: Management of Pediatric Aggressive Mature B-Cell Lymphoma
Clinician who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date February 3, 2021
Updates in the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Sequencing Therapy and the Role of MRD Testing
There is a continuing need to educate hematologists and oncologists about the challenges and special considerations involved in the management of patients with CLL/SLL so that they can make informed clinical decisions and develop an individualized treatment plan for their patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment
Educating clinicians about the biology of MZLs, novel therapeutic approaches and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is it Time to Consider CAR T for All?
There is a clear need for clinicians to receive education regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of treatment-related adverse events and the effective management strategies. More importantly, clinicians should refer appropriate patients for participation in well-designed clinical studies to facilitate the development of CAR T-cell therapies. 
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Pharmacy Updates: Treatment Advances for Pediatric B-Cell Non-Hodgkin's Lymphomas
This is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment for early stage and later stage disease will improve understanding and subsequently, education for patients and caregivers alike.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date November 17, 2020
Recorded Presentation from the NCCN Pharmacy Updates: Treatment Advances for Pediatric B-Cell Non-Hodgkin's Lymphomas
This is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment for early stage and later stage disease will improve understanding and subsequently, education for patients and caregivers alike.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation